![]() In ERASMUS, a phase 2 clinical study, 16 patients (2.0%) developed MDS and 4 (0.5%) developed acute leukemia. Secondary Myelodysplastic Syndrome and Leukemia: In NETTER-1, with a median follow-up time of 76 months in the main study, myelodysplastic syndrome (MDS) was reported in 2.3% of patients receiving LUTATHERA with long-acting octreotide compared with no patients receiving high-dose long-acting octreotide.Withhold dose, reduce dose, or permanently discontinue LUTATHERA based on the severity of myelosuppression. ![]() Among these 15 patients, 5 improved to grade 1, 9 to grade 2, and 1 to grade 3. Fifteen of the 19 patients in whom platelet recovery was not documented had post-nadir platelet counts. The median time to platelet recovery was 2 months. Of the 59 patients who developed thrombocytopenia, 68% had platelet recovery to baseline or normal levels. In NETTER-1, platelet nadir occurred at a median of 5.1 months following the first dose. Myelosuppression: In the NETTER-1 clinical trial, myelosuppression occurred more frequently in patients receiving LUTATHERA with long-acting octreotide compared with patients receiving high-dose long-acting octreotide (all grades/grade 3/4): anemia (81%/0 vs 54%/1%), thrombocytopenia (53%/1% vs 17%/0), and neutropenia (26%/3% vs 11%/0).Minimize radiation exposure to patients, medical personnel, and household contacts during and after treatment with LUTATHERA consistent with institutional good radiation safety practices, patient management procedures, Nuclear Regulatory Commission patient release guidance, and instructions to the patient for follow-up radiation protection at home. Radiation can be detected in the urine for up to 30 days following LUTATHERA administration. Radiation Exposure: Treatment with LUTATHERA contributes to a patient’s overall long-term cumulative radiation exposure and is associated with an increased risk for cancer.NETSPOT Full U.S.LUTATHERA ® (lutetium Lu 177 dotatate) is indicated for the treatment of somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors (GEP-NETs), including foregut, midgut, and hindgut neuroendocrine tumors in adults. Please contact us at 95 for further details. This product has been designated as an orphan drug by the EMA and the FDA. NETSPOT™ is a novel patented kit developed by AAA for the preparation of gallium Ga 68 dotatate for injection, for localization of somatostatin receptor positive neuroendocrine tumors (NETs) in adult and pediatric patients using Positron Emission Tomography (“PET“). NETSPOT™ is a significant improvement over existing diagnostic tools and will enable us to more accurately stage and better manage patients. In a clinical study, NETSPOT™ demonstrated the ability to change management decisions regarding patients in 71% of cases previously imaged with Octreoscan. Saving just one patient from futile surgery can improve the treatment experience overall and significantly reduce the cost of care by reducing repetitive, often frustrating, and limitless diagnostics. NETSPOT™ offers superior sensitivity and accuracy compared to previously available diagnostics for NET patients. Gallium PET/CT also allows for calculation of standardized uptake value, has less whole body radiation, and is performed in less time versus Octreoscan. ![]() Gallium PET/CT is more accurate for staging and superior to Octreoscan SPECT in the detection of overall number of lesions in the body as well as organs and bones. Use of NETSPOT changed patient treatment and management in 71% of patients due to greater specificity compared to Octreoscan. It is a form of octreotide, which binds to a receptor on many NETs called the Somatostatin Receptor. NETSPOT, the new tracer for Gallium 68-Dotatate scan, is the next generation of OCTREOSCAN. PET Imaging Institute of South Florida is proud to offer newly available NETSPOT (Gallium 68-Dotatate) scan: A novel PET/CT tracer for the detection of Neuro Endocrine Tumors (NETs)
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |